Lymphomas in patients with connective tissue disease: Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate

American Journal of Clinical Pathology

Volumn 113, Issue 2, 2000, Pages 212-218

  Menke, David M ^b   Griesser, Henrik ^c   Moder, Kevin G ^c   Tefferi, Ayalew ^a   Luthra, Harvinder S ^c   Cohen, Marc D ^c   Colon Otero, Gerardo ^c   Lloyd, Ricardo V ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c NONE

Author keywords

Connective tissue disease; Immunosuppression; Latent Epstein Barr virus; Lymphoma; p53 protein

Indexed keywords

GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; PROTEIN P53;

ADULT; ARTICLE; CANCER REGRESSION; CELL CYCLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LATENT VIRUS INFECTION; LYMPHOMA; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034003514     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/vf28-e64g-1dnd-lf94     Document Type: Article

References (33)

1. Doussis IA, Pezzella F, Lane DP, et al. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am J Clin Pathol. 1993;99:663-667.
2. Said JW, Barrera R, Shintaku IP, et al. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol. 1992;141:1343-1348.
3. Szekely L, Selivanova G, Magnusson KP, et al. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A. 1993;90:5455-5459.
4. Chen W, Cooper NR. Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappa B activity. J Virol. 1996;70:4849-4853.
5. Kamel OW, van de Rijn M, LeBrun DP, et al. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol. 1994;25:638-643.
6. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943-1949.
7. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed. 1998;65:267-273.
8. Staal SP, Ambinder R, Beschorner WE, et al. A survey of Epstein-Barr virus DNA in lymphoid tissue: frequent detection in Hodgkin's disease. Am J Clin Pathol. 1989;91:1-5.
9. Kamel OW, van de Rijn M, Hanasono MM, et al. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma. 1995;16:363-368.
10. van de Rijn M, Chang PP, Cleary ML, et al. Molecular features of Epstein-Barr virus associated lymphoproliferative lesions in patients with rheumatic diseases [abstract]. Mod Pathol. 1995;8:122A.
11. van de Rijn M, Cleary ML, Variakojis D, et al. Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:638-642.
12. Lehtinen T, Luostarinen T, Dillner J, et al. Serum p53 accumulation and altered antibody responses to Epstein-Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin. Br J Haematol. 1996;93:104-110.
13. Niedobitek G, Rowlands DC, Young LS, et al. Overexpression of p53 in Hodgkin's disease: lack of correlation with Epstein-Barr virus infection. J Pathol. 1993;169:207-212.
14. Lehtinen T, Isola J, Aine R, et al. Accumulation of p53 protein correlates with tumour proliferative activity in EBV positive Burkitt's lymphoma. Hematol Oncol. 1992; 10:273-279.
15. Anwar N, Kingma DW, Bloch AR, et al. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations. Cancer. 1995;76:1245-1252.
16. Edwards RH, Raab-Traub N. Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. J Virol. 1994;68:1309-1315.
17. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
18. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
19. Swerdlow SH. Post-transplant lymphoproliferative disorders: a morphologic, phenotypic and genotypic spectrum of disease. Histopathology. 1992;20:373-385.
20. Myers JL, Kurtin PJ, Katzenstein AL, et al. Lymphomatoid granulomatosis: evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol. 1995;19:1300-1312.
21. Peiper SC, Myers JL, Broussard EE, et al. Detection of Epstein-Barr virus genomes in archival tissues by polymerase chain reaction. Arch Pathol Lab Med. 1990;114:711-714.
22. Trainor KJ, Brisco MJ, Wan JH, et al. Gene rearrangement in B-and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood. 1991;78:192-196.
23. Ralph QM, Brisco MJ, Joshua DE, et al. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene. Blood. 1993;82:202-206.
24. Banks PM, Witrak GA, Conn DL. Lymphoid neoplasia following connective tissue disease. Mayo Clin Proc. 1979;54:104-108.
25. Thomason RW, Craig FE, Banks PM, et al. Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Mod Pathol. 1996;9:261-266.
26. Kamel OW. Iatrogenic lymphoproliferative disorders in nontransplantation settings. Semin Diagn Pathol. 1997;14: 27-34.
27. Depper JM, Bluestein HG, Zvaifler NJ. impaired regulation of Epstein-Barr virus-induced lymphocyte proliferation in rheumatoid arthritis is due to a T cell defect. J Immunol. 1981;127:1899-1902.
28. Tosato G, Steinberg AD, Yarchoan R, et al. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest. 1984;73:1789-1795.
29. Vaughan JH. Immune system in rheumatoid arthritis: possible implications in neoplasms. Am J Med. 1985;78:6-11.
30. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med. 1985;78:29-32.
31. Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med. 1985;78(suppl 1A):15-21.
32. Kinlen LJ. Malignancy in autoimmune diseases. J Autoimmun. 1992;5(suppl A):363-371.
33. Matteson EL, Hickey AR, Maguire L, et al, and members of the Rheumatoid Arthritis Azathioprine Registry Steering Committee. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. J Rheumatol. 1991;18:809-814.